Chimeric antigen receptors targeting tim-1

Abstract

The invention provides chimeric antigen receptors (CARs) that specifically bind to the T-cell immunoglobulin and mucin domain 1 (TIM-1) protein. The invention further relates to modified immune cells,e.g., T or NK cells, comprising such CARs, CAR-encoding nucleic acids, CAR-encoding vectors, and methods of making such compositions. The invention further relates to methods for therapeutic use of these CARs and modified immune cells for the treatment of a condition, disorder, or disease associated with cells expressing TIM-1 (e.g., cancer).

Description

[0001] Related application open

[0002] This application claims the benefit of U.S. Provisional Application Serial No. 62 / 445,976, filed January 13, 2017, which is hereby incorporated by reference in its entirety.

[0003] sequence public

[0004] This application includes as part of its disclosure the Biological Sequence Listing in a file named "56867o1000.txt" and 193,169 bytes in size, created on January 12, 2018, which is hereby incorporated by reference in its entirety enter. technical field

[0005] The invention disclosed herein relates to chimeric antigen receptors (CARs) that bind to antigenic T cell immunoglobulin domain and mucin domain 1 (TIM-1 ) proteins and uses of such CARs. In particular, chimeric antigen receptors are provided comprising an antigen binding domain that binds TIM-1, a transmembrane domain, and one or more intracellular signaling domains. The nucleotide sequence encoding the anti-TIM-1 CAR construct and the amino acid sequence comprising the ...

Images